Zacks Industry Outlook Highlights: Life Technologies, Thermo Fisher Scientific, Bayer, Conceptus and Becton, Dickinson and Co.

     Zacks Industry Outlook Highlights: Life Technologies, Thermo Fisher
          Scientific, Bayer, Conceptus and Becton, Dickinson and Co.

PR Newswire

CHICAGO, May 16, 2013

CHICAGO, May 16, 2013 /PRNewswire/ --Today, Zacks Equity Research discusses
the U.S. Medical Technologies, including Life Technologies Corporation
(Nasdaq:LIFE), Thermo Fisher Scientific (NYSE:TMO), Bayer (OTC:BAYRY),
Conceptus Inc. (Nasdaq:CPTS) and Becton, Dickinson and Company (NYSE:BDX).


A synopsis of today's Industry Outlook is presented below. The full article
can be read at 


As expected, MedTech mergers and acquisitions (M&A) are heating up in 2013.
Finally, the much-hyped takeover battle forLife Technologies Corporation
(Nasdaq:LIFE) came to an end last month with Thermo Fisher Scientific
(NYSE:TMO) emerging as the clear winner.

For most of the last seven years, Thermo Fisher has supported its business
momentum by acquiring several entities. Nevertheless, the proposed acquisition
of Life Technologies is the biggest-ever deal for the company since its
inception in 2006. The takeover will inevitably strengthen Thermo Fisher's
global foothold and commercial reach.

It's a Buyer's Market

Medical device M&As are not stopping there. Wary of an uncertain economy,
MedTech companies have resorted to the acquisition route to harness their
strength and diversify offerings.

Last month, in a bid to strengthen its contraceptive portfolio, Bayer
(OTC:BAYRY) inked a deal to buy contraceptive device-maker Conceptus Inc.
(Nasdaq:CPTS) for approximately $1.1 billion in cash. This impending
acquisition will add the Essure permanent (non-surgical) birth control system
to Bayer's product portfolio. The transaction is expected to close by

In Mar 2013,

Becton, Dickinson and Company



) acquired AustriA-based Cato Software Solutions, the manufacturer of "catoA?
and chemocatoA?" software, a suite of comprehensive medication safety
solutions for pharmacy intravenous medication preparation, physician therapy
planning and nurse bedside documentation.

Also, low global penetration and demand outstripping supply provide a positive
long-term thesis for investing in the blood processing and supply chain
management industry.

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.